Ependymoma is a type of rare childhood cancer that occurs in the brain and spinal cord. Survival statistics are generally disappointing with a 5-year survival of 50-64%. The standard of care for ependymoma is maximal surgical resection followed by radiation therapy directed at the primary site of disease.

Radiation therapy is associated with immediate and long-term toxicities in children, especially young children. For this reason, it has been the practice of some doctors not to give radiation therapy to children with ependymoma when the tumor has been completely surgically removed. The investigators who designed this study have created strict measures to choose those who will not receive additional treatment after surgery and careful follow-up to minimize the risks to those who are assigned to observation only.

To collect information about the patient's leukemia and to seek the optimal treatment for children with ALL based on the individual level of risk of the cancer coming back after treatment. The risk groups are defined as a result of recent research conducted by the Children's Oncology Group (COG). We would like to learn if the use of an experimental intrathecal therapy (ITT), which has been given to many people with ALL and has been well tolerated, would be better at preventing relapse in the central nervous system and improve disease outcomes in children with High Risk ALL.

The Center for International Blood and Marrow Transplant Research (CIBMTR ) keeps a research database. It uses this database to collect and study the medical data for patients that have received Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries. It also collects and studies data from donors who give bone marrow or peripheral blood stem cells (PBSCs). These therapies are used to treat cancer and other diseases. The purpose of this study is to add more data to the database. Participants will have medical data (data about their disease, transplant or cellular therapy) collected before and after transplant cellular therapy, and once a year afterwards for life.

The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy.